1
项与 Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine(NIAID) 相关的临床试验A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants
To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also test the safety of and immune response to a protein vaccine given alone.
100 项与 Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine(NIAID) 相关的临床结果
100 项与 Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine(NIAID) 相关的转化医学
100 项与 Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine(NIAID) 相关的专利(医药)
100 项与 Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine(NIAID) 相关的药物交易